Vera Therapeutics Targets 50% Patient Coverage by Year-End Following TRUTAKNA Launch
Vera Therapeutics (VERA) has identified the third quarter as a pivotal turning point for the company following the FDA's accelerated approval of its product, TRUTAKNA. The treatment is specifically designed to reduce proteinuria in adults suffering from primary IgA nephropathy. Management has set an ambitious commercial goal to achieve 50% coverage of eligible lives by the end of the year. Looking further ahead, the company is working toward securing full FDA approval for TRUTAKNA, which is currently projected for mid-2027.
Tickers: $VERA
Topics: earnings call FDA approval IgA nephropathy product launch
Read the full article at Seeking Alpha
Part of the story Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch (9 articles)